ScreenerHero

PLYX Polaryx Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · polaryx.com
2.090USD-0.48%Mkt Cap: 98.95M $P/E: —

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the Un…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap98.95M USD
Enterprise Value93.13M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.98M USD
Revenue/Share—
Last Price2.090 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B9.59
EPS (TTM)-0.14
EPS (Forward)—
52W Range
1.8550% of range48.91
52W High48.91 USD
52W Low1.855 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-196.82%
ROA-173.79%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.94M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-2.11%
Net Debt-11.54M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio13.53
Quick Ratio13.22
Book Value/Sh0.22 USD
Cash/Share0.23 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)7.500 USD
Upside (mean)+258.9%
Target Range6.000 USD – 10.00 USD
6.000+258.9% to mean10.00
# Analysts4
Ownership
Shares Out.47.34M
Float7.17M
Insiders69.92%
Institutions4.40%
Short Interest
Short Ratio2.4d
Short % Float0.87%
Short % Out.0.37%
Shares Short186.77K
Short (prev mo.)249.04K
Technical
SMA 502.106 (-0.7%)
SMA 2003.845 (-45.7%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)36.32K
Avg Vol (10d)30.29K
Technical Indicators
RSI (14)50.2
MACD-0.0067
MACD Signal-0.0118
MACD Hist.+0.0051
BB Upper2.173 USD
BB Middle2.074 USD
BB Lower1.975 USD
BB Width9.52%
ATR (14)0.1146 USD
Vol Ratio (20d)0.39x